Biocon Limited (BOM:532523)
364.60
+4.00 (1.11%)
At close: Aug 7, 2025
Paramount Global Revenue
In the fiscal year ending March 31, 2025, Biocon had annual revenue of 152.62B INR with 3.43% growth. Biocon had revenue of 44.17B in the quarter ending March 31, 2025, with 12.76% growth.
Revenue
152.62B
Revenue Growth
+3.43%
P/S Ratio
2.91
Revenue / Employee
9.67M
Employees
16,315
Market Cap
458.18B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 152.62B | 5.06B | 3.43% |
Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
Mar 31, 2021 | 71.43B | 8.43B | 13.37% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,765.41B |
HDFC Bank | 2,736.06B |
Bharti Airtel | 1,839.41B |
Tata Consultancy Services | 2,561.48B |
ICICI Bank | 2,054.85B |
State Bank of India | 3,503.84B |
Infosys | 1,672.76B |
Hindustan Unilever | 639.28B |
Biocon News
- 17 days ago - Biocon Biologics launches Nepexto, a biosimilar to Enbrel, in Australia - Business Upturn
- 24 days ago - Top stocks in focus on July 16: Biocon, Dixon Technologies, IndiGo, ICICI Lombard, HDFC Life and more - Business Upturn
- 4 weeks ago - Biocon to announce Q1 FY26 results on August 7 - Business Upturn
- 5 weeks ago - It’s wrong to blame Covid jabs for cardiac arrests: Biocon chief Kiran Mazumdar-Shaw - The Times of India
- 5 weeks ago - 'Caution Not Anti-Science': Siddaramaiah On Covid Vaccine-Sudden Death Claim - NDTV
- 5 weeks ago - Biocon Chief Counters Siddaramaiah's Covid Vaccine-Heart Attack Link Claim - NDTV
- 5 weeks ago - Biocon Biologics gets marketing authorisation from EC for Denosumab Biosimilars Vevzuo and Evfraxy - Business Upturn
- 5 weeks ago - India’s Biocon Aims to Lead Copycat Wegovy Sales in Canada From Next Year - Financial Post